Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ADC Bio Extends with Tech. Service Lab

Published: Thursday, May 09, 2013
Last Updated: Thursday, May 09, 2013
Bookmark and Share
R&D emphasis for additional £125,000 facility.

ADC Bio has extended its North Wales, UK facility with a new £125,000 Technical Service Laboratory. Commissioned last month (April), the new lab at St. Asaph will meet growing demand for the company's R&D services from developers of niche anti-cancer drugs based on antibody drug conjugates (ADCs).

The company's specialist experience in working with complex anti-cancer technologies and rapidly accelerating ADC drug developments have boosted demand for its R&D capabilities.

The additional facility at St. Asaph will offer customers a range of services including ADC screening, process development and scale up. The lab is equipped to manufacture at mg to 10s of gram scale to toxicology batch scale; this includes manufacture of materials compatible with pivotal In Vivo toxicology studies. Initially, the development has added two more science staff, bringing the technical team up to four.

The laboratory brings together analytical and preparative equipment and skill sets in one integrated space. Capabilities include HPLC, ELISA and Gel electrophoresis, along with development and preparative scale chromatography and cross flow/normal flow filtration systems.

"The number of ADCs in trials and pre-clinical development has dramatically increased over the past 18 months", notes ADC Bio's CEO Charlie Johnson. "Limited capacity in the ADC space is translating into surging demand for outsourced ADC process and purification development and testing".

He added: "Against this background, expanding our R&D lab capacity enables earlier partnering with customer programmes, increases our service offer and closely complements our main innovation activity".

ADC Bio's original lab will now be dedicated to continuing development of the company's "Lock and Release" solid phase immobilisation technology for high-purity processing. Prototype "Lock and Release" platforms are currently under evaluation by key clients.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!